All In Biotech

Drug Trial Radar · NCT05197842

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Feb 22, 2022

Primary completion

Mar 19, 2025

Study completion Mar 19, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.

Conditions

  • ANCA-associated Vasculitis

Interventions

  • BDB-001 injectionDrug

    Intravenously administered

  • CyclophosphamideDrug

    Intravenously administered

  • GlucocorticoidsDrug

    Orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients achieving disease complete remission or partial remission assessed by Birmingham Vasculitis Activity Score (BVAS)Time frame: 12 weeks

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • The Second hospital Of Anhui Medical University

    Hefei, Anhui, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Peking University International Hospital

    Beijing, Beijing Municipality, China

  • Guangxi Academy of Medical Sciences,The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi Zhuang Autonomous Region (gzar), China

  • The Second hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Third hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The First Affiliated Hospital of Henan University of science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Tongji Hospital,Tongji Medical college of Hust

    Wuhan, Hubei, China

  • Xiangya Hospital Central South University (Nephrology Department)

    Changsha, Hunan, China

  • Xiangya Hospital Central South University(Rheumatism Immunity Branch)

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Shengjing Hospital of China Medical University

    Shengyang, Liaoning, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia Hui Autonomous Region(NHAR), China

  • Zhongshan hospital,Fudan University

    Shanghai, Shanghai Municipality, China

  • Xijing Hospital

    Xi’an, Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi’an, Shanxi, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.